hot sale /High quality Doxercalciferol suppulier

Superiority:

hot sale /High quality Doxercalciferol suppulier

Doxercalciferol is a synthetic vitamin D2 analog introduced in the US as Hectorol for the treatment of secondary hyperparathyroidism (SHPT) in patients with end-stage renal failure. It is actually 1-alpha-hydroxyvitamin D2 (one-alpha- D2) and can be synthesized by direct hydroxylation of vitamin D2 tosylate or in 5 steps from ergosterol. Doxercalciferol itself is inactive until metabolized by the liver into active 1,24-dihydroxyvitamin D2, showing a pharmacokinetic profile similar to calcitriol. During placebo-controlled clinical trials, patients with moderate to severe SHPT were treated with 1-alpha-D2 (10 μg doses) for 16 to 24 weeks; in 9 patients out of 10, blood levels of parathyroid hormone were considerably reduced, so maintaining a good control of the parathyroid hyperplasia. Moreover, only a moderate tendency to raise calcium and phosphate was observed. Doxercalciferol is orally-active and less toxic than other vitamin D analogs like alfacalcidol; it shows differentially controlled effects and has an improved safety profile compared to calcitriol

Doxercalciferol (other name: 1α-hydroxyvitamin D₂), a synthetic vitamin D₂ analog, was first synthesized from ergosterol [E0018].¹⁾ It is a prodrug requiring hepatic metabolism to the active metabolite 1α,25-dihydroxyvitamin D₂ (1α, 25-(OH)₂D₂), a biologically active form of vitamin D₂.²⁾ The active vitamin D₂ binds the vitamin D receptor (VDR) to result in the selective activation of vitamin D responsive pathway. It has been reported that doxercalciferol reduces parathyroid hormone (PTH) levels by inhibiting PTH synthesis and secretion.³⁾ In clinical, doxercalciferol is used for the treatment of secondary hyperparathyroidism (2HPT) and metabolic bone disease.^3,4) (The product is for research purpose only.)

Synthetic vitamin D prohormone. A new active Vitamin D analog which inhibits growth of human neuroblastoma. Antihyperparathyroid